Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
8.52 CNY | -3.18% | -2.29% | -28.88% |
May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-28.88% | 436M | |
+55.55% | 59.28B | |
+43.40% | 40.94B | |
-4.71% | 40.17B | |
-5.56% | 28.69B | |
+13.76% | 26.63B | |
-22.00% | 18.89B | |
+31.50% | 12.46B | |
+2.16% | 12.42B | |
+25.70% | 12.26B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Gets US Patent for RenMab Mice